[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
March 1985

Intravenous Etidronate in the Management of Malignant Hypercalcemia

Author Affiliations

From the Orthopedic Hospital, Los Angeles (Dr Ryzen); Department of Oncology, Brooke Army Medical Center, San Antonio, Tex (Dr Troxell); Department of Human Oncology, University of Wisconsin, Madison (Dr Benson); Cross Cancer Institute, Edmonton, Alberta (Dr Paterson); Division of Hematology/Oncology, University of Chicago Hospital and Clinics (Dr Shepard); and Proctor & Gamble Co, Cincinnati (Dr Martodam and Mr Hicks).

Arch Intern Med. 1985;145(3):449-452. doi:10.1001/archinte.1985.00360030089018

• The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. We have used intravenously administered etidronate disodium as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level less than or equal to 1.5 mg/dL were allowed on study. Treatment consisted of intravenously administered etidronate disodium at 7.5 mg/kg/day in 250 mL of saline infused over two hours on 1, 2,3, or 4 consecutive days. The serum calcium level in 19 (73%) of 26 patients returned to the normal range with a mean response time of 3±2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non—small-cell lung cancer, and multiple myeloma. Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.

(Arch Intern Med 1985;145:449-452)